ArticlePharmaceuticals (Basel, Switzerland)2022
Siccanin Is a Dual-Target Inhibitor of
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Targeting Mitochondrial Function inInternational journal of molecular sciences · 2025Review
- Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.ACS infectious diseases · 2024Article
- Dobinin K Displays Antiplasmodial Activity through Disruption ofMolecules (Basel, Switzerland) · 2024Article
- Article
- Special Issue "Drug Candidates for the Treatment of Infectious Diseases".Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Breakthroughs in the development of antibiotics, antifungals and antiparasitics targeting the pathogens' respiratory chain.Critical reviews in biochemistry and molecular biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.